• BCA Protein Quantification Kit K4102 Workflow

  2026-09-24

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures total protein in dilute samples, including cell lysates, to support concentration checks and sample normalization. It is intended for scientific research—not diagnostic, clinical, or medical testing—and its stated measurement range and detergent tolerance should not be interpreted as universal compatibility with every sample matrix.

• Staurosporine: Kinase Dependence in Metastasis

  2026-09-23

  Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor that can reveal how kinase activity influences cancer-cell survival, motility, and invasion. This article develops an assay framework linking Staurosporine perturbation to the TBXA2R–ERM metastatic signaling axis while emphasizing interpretation limits and experimental controls.

• Remdesivir (GS-5734): Polymerase Strategy

  2026-09-22

  A mechanistic and translational analysis of Remdesivir (GS-5734), connecting polymerase biology, coronavirus and filovirus validation, and emerging structural insights from the Nipah virus L-P complex.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-09-22

  Tamoxifen is both a selective estrogen receptor modulator for cancer-focused assays and a temporal switch for CreER-mediated gene knockout. This practical guide connects formulation, induction design, developmental safety controls, and troubleshooting to improve reproducibility across cell and mouse workflows.

• APEX-RNA-MS Maps RNA Modifications in Condensates

  2026-09-21

  Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a workflow that combines APEX2 proximity labeling with modified-nucleoside LC-MS to measure RNA modification profiles within defined protein neighborhoods. The study links m6A and m5C to DNA damage foci and shows that modified tRNAs are associated with G3BP1 and accumulate in arsenite-induced stress granules.

• UK-5099: From Pyruvate Transport to Immune Insight

  2026-09-21

  A translational framework for using UK-5099 and PF-1005023 to connect mitochondrial pyruvate transport with bioenergetics, glucose regulation, and standardized immunometabolic assays.

• Molnupiravir Protects Mice from Bourbon Virus Disease

  2026-09-20

  A 2025 Journal of Virology study shows that molnupiravir inhibits Bourbon virus replication in cell culture and improves survival, clinical disease, thrombocytopenia, and organ pathology in infected mice. Its combination of prophylactic and delayed-treatment experiments provides a useful preclinical framework for evaluating therapies against emerging tick-borne RNA viruses.

• GDC-0068 (RG7440): Pan-AKT Research Guide

  2026-09-19

  GDC-0068, also called RG7440, is an ATP-competitive pan-AKT inhibitor that targets Akt1, Akt2, and Akt3. Its preclinical profile supports studies of PI3K/Akt/mTOR signaling, especially in models with PTEN loss or PI3K-pathway activation, while its phospho-Akt response requires careful interpretation.

• AG-490 Workflow for JAK2/STAT6 Signaling Studies

  2026-09-19

  AG-490 (Tyrphostin B42) provides a practical pharmacological test of JAK2-linked signaling in exosome–macrophage models, including hepatocellular carcinoma research. This guide converts the reported SNORD52–JAK2/STAT6 finding into a controlled workflow with dose design, pathway readouts, and troubleshooting safeguards.

• Plerixafor (AMD3100): From Axis to Action

  2026-09-18

  A translational guide to using Plerixafor (AMD3100) to interrogate CXCL12/CXCR4 biology across cancer metastasis, stem cell trafficking, and immune-cell mobilization—while positioning emerging inhibitors such as A1 in the right experimental context.

• ROR1 Biology Meets Translational Assay Strategy

  2026-09-17

  A translational framework for using Anti-ROR1 Antibody (Zilovertamab) to connect target engagement, Wnt5a-induced ROR1 signaling inhibition, and functional evidence—while applying lessons from deoxynivalenol hepatotoxicity research without overstating cross-domain relevance.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-17

  The reference study shows that high-grade glioma cells lacking functional ATRX are more vulnerable to multi-targeted receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells. Its drug-screening and combination data support ATRX status as an important variable for interpreting RTK inhibitor studies and for evaluating RTK inhibitor–temozolomide strategies.

• AMPK, ULK1, and Autophagy Under Energy Stress

  2026-09-16

  The reference study overturns the simplified view that AMPK uniformly activates autophagy during energy stress. It shows that AMPK can suppress ULK1-dependent autophagy initiation while protecting the autophagy machinery, creating a context-dependent response that helps cells survive transient energy crises and recover homeostasis.

• Ibuprofen Workflows for Cancer Research

  2026-09-16

  Build reproducible Ibuprofen experiments that connect COX inhibition with apoptosis, proliferation, and cell-cycle readouts. This workflow also adapts a protein–drug interaction strategy from a mubritinib–albumin study while clearly separating transferable assay logic from compound-specific evidence.

• Simvastatin (Zocor) in Lipidomics Assay Design

  2026-09-15

  Simvastatin (Zocor) can serve as more than a cholesterol synthesis inhibitor: it provides a mechanistic comparator for lipidomics-informed HepG2 assays. This guide connects HMG-CoA reductase biology with experimental decisions about lipid accumulation, viability, apoptosis, and interpretation.

7936 records 1/530 page Next 12345 下5页 Last page